Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential To Identify Novel Drug Combinations In JMML
Portfolio Pulse from Benzinga Newsdesk
Notable Labs (NASDAQ:NTBL) has published data from an ex vivo study demonstrating the potential of its Predictive Precision Medicine Platform (PPMP) to identify more effective pre-hematopoietic stem cell transplantation (pre-HSCT) regimens for the treatment of juvenile myelomonocytic leukemia (JMML). The study found that tretinoin, a standard-of-care agent in acute promyelocytic leukemia (APL), enhanced the ex vivo effects of FLA and AZA, suggesting a potential rationale for use of CD38-targeting agents to further enhance the envisioned treatment effect.
November 09, 2023 | 10:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Notable Labs' study demonstrates the potential of its PPMP to identify more effective treatments for JMML. This could potentially lead to new treatment regimens and improve the company's market position.
The successful demonstration of the potential of Notable Labs' PPMP to identify more effective treatments for JMML could lead to the development of new treatment regimens. This could improve the company's market position and potentially increase its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100